基因流生物科学公司扩大了针对肌肉疾病的SIRT6治疗专利. Genflow Biosciences expands patents for SIRT6 treatments for muscular diseases.

基因流生物科学公司已扩大对SIRT6蛋白的知识产权保护, 包括肌肉疾病如虚弱综合征和皮症的治疗. Genflow Biosciences has expanded its intellectual property protection for the SIRT6 protein to include treatments for muscular diseases like frailty syndrome and sarcopenia. 该公司宣布国际发布了一项新专利, 涵盖工程变种和药物配方. The company announced the international publication of a new patent covering engineered variants and pharmaceutical formulations. 这一举动加强了Genflow在长寿医学领域的地位, 并支持其针对与年龄相关疾病的基因疗法. This move strengthens Genflow's position in longevity medicine and supports its pipeline of gene therapies targeting age-related conditions.